Marie‐Ange Mouret‐Reynier

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

François‐Clément Bidard, Virginia Kaklamani, Patrick Neven et al. · Journal of Clinical Oncology · 2022 · 626 citations · Full text

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis

Céline Lefèbvre, Thomas Bachelot, Thomas Filleron et al. · PLoS Medicine · 2016 · 388 citations · Full text

Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer

Mathilde Bayet‐Robert, Fabrice Kwiatowski, Marianne Leheurteur et al. · Cancer Biology & Therapy · 2010 · 386 citations · Full text

Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial

Angelo Di Leo, Stephen Johnston, Keun Seok Lee et al. · The Lancet Oncology · 2017 · 377 citations

Advanced Breast Cancer, Breast Oncology, Oncology +11